TWST
Twist Bioscience Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$124.72
−3.10%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−75.5x
Market Cap
$8.21B
MomentumView details →
1D Return
−3.10%
YTD Return
+292.96%
RSI (14)
49.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−75.5x
Market Cap
$8.21B
RSI (14)
49.1
MomentumView details →
1D Return
−3.10%
YTD Return
+292.96%
SummaryUpdated Jun 1, 2026
Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology company founded in 2013 and headquartered in South San Francisco, California. The company went public in October 2018 and has established itself as a leader in DNA synthesis technology. Twist operates a proprietary silicon-based DNA synthesis platform that enables the manufacturing of synthetic DNA by literally "writing" DNA sequences on silicon chips, similar to how computer chips are manufactured. The company has grown from a startup to serving over 3,500 customers globally across academic, biotechnology, pharmaceutical, and industrial markets.
Similar companies
Latest newsMore news →
Brandywine Managers LLC acquired a new position in Twist Bioscience Corporation, purchasing 20,970 shares valued at approximately $2.16 million during the second quarter, as disclosed in a Form 13F filing.11d agoAnthropic published research showing its Claude models (Mythos Preview and Opus 4.8) autonomously ran protein-design campaigns, a key step in drug discovery, with designs yielding working molecules on 14 out of 15 targets at success rates above industry norms.16d agoAnthropic named Twist Bioscience Corp an independent evaluator in a new AI-driven protein design campaign.16d ago